InMed Pharmaceuticals to Merge with Mentari Therapeutics in $290M Financing Deal
InMed Pharmaceuticals (NASDAQ:INM) is merging with private biotech company Mentari Therapeutics, backed by a $290 million financing round. The merger shifts InMed's focus toward migraine prevention therapies and will fund operations through key clinical milestones until at least 2028.
Tickers: $INM